欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Immunology/Inflammation > Cenicriviroc

浏览历史

S85553

Cenicriviroc

源叶(MedMol) 97%
  • 英文名:
  • Cenicriviroc
  • 别名:
  • CAS号:
  • 497223-25-3
  • 分子式:
  • C41H52N4O4S
  • 分子量:
  • 696.94
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S85553-1mg 97% ¥250.00元 2 - - - EA 加入购物车
源叶(MedMol) S85553-5mg 97% ¥1040.00元 6 - - - EA 加入购物车
源叶(MedMol) S85553-10mg 97% ¥1530.00元 5 - - - EA 加入购物车
源叶(MedMol) S85553-50mg 97% ¥4080.00元 5 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述:

    Cenicriviroc (CVC, TAK-652, TBR-652) 是一种有效的、口服活性的 CC chemokine receptor 2 (CCR2) 和 CCR5 的双效抑制剂。Cenicriviroc 还可抑制 HIV-1 和 HIV-2 并具有有效的抗炎和抗感染活性

  • 靶点: CCR2;CCR5;HIV-1;HIV-2;HIVProtease;CCR
  • 体内研究:
    Cenicriviroc significantly reduces monocyte/macrophage recruitment in vivo at doses >= 20 mg/kg/day (p < 0.05). At these doses, Cenicriviroc shows antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, Cenicriviroc significantly reduces the nonalcoholic fatty liver disease activity score (p < 0.05 vs. controls). Cenicriviroc treatment has no notable effect on body or liver/kidney weight.
  • 细胞实验: Cell lines: activated macrophages Concentrations: 1 μM Incubation Time: 2 h Method: TG is injected intraperitoneally into male C57BL/6 mice and activated macrophages are collected 48 hours later by peritoneal lavage. Chemotaxis is assayed using a Transwell1 Chamber with a 5 μm-pore size polycarbonate filter. Briefly, cells are incubated for 2 hours in the presence of 1 nM CCL2 and/or 1 μM Cenicriviroc (dissolved in dimethyl sulfoxide with 0.5% acetic acid and diluted 1:1000 with serum-free Roswell Park Memorial Institute-1640 medium and 0.5% bovine serum albumin). Cells are harvested from the lower compartment and analyzed by flow cytometry to enumerate F4/80+CD11b+ macrophages using a 3-laser BD FACSCanto. Results are analyzed using FlowJo software.
  • 动物实验: Animal Models: 8–10 weeks old male C57BL/6 mice, 10–12 weeks old male Sprague-Dawley rats Dosages: 5 mg/kg, 20 mg/kg, 100 mg/kg, 30 mg/kg Administration: Oral gavage, IP
  • 参考文献:
    1. Jacob Lalezari, et al. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. 2. Eric Lefebvre, et al. PLoS One. 2016 Jun 27;11(6):e0158
  • 溶解性: Soluble  in  DMSO、Ethanol
  • 保存条件: 2-8℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.435 ml 7.174 ml 14.348 ml
    5 mM 0.287 ml 1.435 ml 2.87 ml
    10 mM 0.143 ml 0.717 ml 1.435 ml
    50 mM 0.029 ml 0.143 ml 0.287 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。